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Summary. In a typical case–control study, exposure information is collected at a single time point for the cases and controls.
However, case–control studies are often embedded in existing cohort studies containing a wealth of longitudinal exposure
history about the participants. Recent medical studies have indicated that incorporating past exposure history, or a constructed
summary measure of cumulative exposure derived from the past exposure history, when available, may lead to more precise
and clinically meaningful estimates of the disease risk. In this article, we propose a ﬂexible Bayesian semiparametric approach
to model the longitudinal exposure proﬁles of the cases and controls and then use measures of cumulative exposure based
on a weighted integral of this trajectory in the ﬁnal disease risk model. The estimation is done via a joint likelihood. In
the construction of the cumulative exposure summary, we introduce an inﬂuence function, a smooth function of time to
characterize the association pattern of the exposure proﬁle on the disease status with diﬀerent time windows potentially
having diﬀerential inﬂuence/weights. This enables us to analyze how the present disease status of a subject is inﬂuenced by
his/her past exposure history conditional on the current ones. The joint likelihood formulation allows us to properly account
for uncertainties associated with both stages of the estimation process in an integrated manner. Analysis is carried out in a
hierarchical Bayesian framework using reversible jump Markov chain Monte Carlo algorithms. The proposed methodology is
motivated by, and applied to a case–control study of prostate cancer where longitudinal biomarker information is available
for the cases and controls.
Key words: Adaptive knot selection; Exposure trajectory; Inﬂuence function; Odds ratio; Regression spline; Risk score
diagnostics; Semiparametric modeling.
1. Introduction
In a typical case–control study, subjects are sampled con-
ditional on disease status and then exposure history is ret-
rospectively retrieved and assessed. Case–control studies are
often embedded in large cohorts where repeated/single mea-
sures on past exposure information can be obtained for all
the study subjects, and thus for the selected case–control
sample. Many cohort studies store serum, tissue, and other
bio-specimen samples for all enrolled subjects and a case–
control design can be used to assay selected case–control sam-
ples instead of assaying the entire cohort. This retrospective
design thus leads to cost and resource saving when expen-
sive assays are not feasible for a large cohort (Ernster, 1994;
Breslow, 1996). In particular, we consider the setting of a large
cohort study where repeated measures on biological samples
(like blood) have been archived for all study subjects. A case–
control design is then employed to select samples for which a
biomarker or a potential risk factor will be assayed/measured,
after the study period is over. Thus case–control status is
determined at the conclusion of the follow-up period. The
scientiﬁc/statistical question is whether we can/should use
all of the past measures and assay all available archived sam-
ples for selected cases and controls to infer about disease risk.
Thus our goal is to construct measures of cumulative expo-
sure to characterize disease–exposure association using avail-
able longitudinal exposure data (Thomas, 1983, 1988) and to
provide odds ratios that are able to compare diﬀerent types
of exposure time trajectories.
Some recent medical studies have indicated that incorpo-
rating the entire exposure history, when available, may lead to
more precise and clinically meaningful estimation of disease
risk. For example, Lewis et al. (1996) report that by integrat-
ing the lifetime history of oral contraceptive use, they obtain
scientiﬁcally more plausible inference on the odds ratio cor-
responding to the use of oral contraceptive for risk of venous
thromboembolism than that provided by measuring current
use of oral contraceptive in a matched case–control study.
Such an analysis may also provide insight on how the present
disease status of a subject is being inﬂuenced by past exposure
conditional on the current exposure. In this article, we present
C© 2012, The International Biometric Society 361
362 Biometrics, June 2012
a Bayesian semiparametric approach for utilizing past longitu-
dinal exposure history in case–control studies. The Bayesian
joint model we propose estimates the time-varying exposure
trajectories as well as the function that captures their inﬂu-
ence on disease risk (which we call the inﬂuence function) in
a ﬂexible nonparametric way. The cumulative exposure eﬀect
is then aggregated over time, by integrating the exposure tra-
jectory weighted by the inﬂuence function over a given time
interval. We are then able to compare the odds of disease cor-
responding to diﬀerent shapes of exposure proﬁles as well as
the relative contribution of diﬀerent time windows using the
disease risk model.
Statistical analysis of case–control data was pioneered by
Cornﬁeld (1951, 1961) and Mantel and Haenszel (1959), and
many important contributions followed over the next half cen-
tury (Breslow et al., 1978; Prentice and Pyke, 1979; Zelen
and Parker, 1986; Seaman and Richardson, 2001, 2004, to
name a few). However, rigorous statistical methods for incor-
porating longitudinally varying exposure information under
case–control sampling have not yet been adequately devel-
oped. Moulton and Monique (1991) consider a similar prob-
lem with time-varying binary/categorical exposure and carry
out a time-stratiﬁed analysis, then combine the regression
coeﬃcients across time to create time-speciﬁc summary quan-
tities of interest. Park and Kim (2004) consider a serial
case–control study where subjects could be cases at one pre-
determined sampling time and controls at another sampling
window, leading to time-varying case–control status and ex-
posure information. They illustrate that a naive general-
ized estimating equation approach with compound symme-
try correlation structure, which is commonly used under a
prospective design does not work under case–control sampling
design. Freedman et al. (2009) incorporate smoking history as
a time-varying exposure in a case–control study using a sur-
vival analysis framework.
In the present article, we do not treat the exposure trajecto-
ries as a time-varying exposure in our ﬁnal disease risk model,
but create a cumulative measure that reﬂects the varying con-
tribution of the diﬀerent time intervals through the inﬂuence
function. In analyzing the eﬀect of a longitudinally varying
exposure proﬁle on a binary outcome variable (like disease
status), some of the well-recognized challenges are: (1) The
longitudinal exposure observations may be unbalanced in na-
ture, i.e., the number of observations and also the observation
times may diﬀer from subject to subject; (2) The exposure
trajectory may be highly nonlinear; (3) The exposure obser-
vations may be subject to considerable measurement error;
and (4) The eﬀect of the exposure proﬁle on the disease out-
come may itself be complex and can even change over time.
In view of the above challenges, we propose to use functional
data analytic techniques, specially nonparametric regression
methodology to model both the time-varying exposure pro-
ﬁle and also the inﬂuence pattern of the exposure proﬁle on
the binary outcome to account for any smooth time-varying
patterns of inﬂuence. Speciﬁcally, we model the underlying
exposure trajectory and the eﬀect pattern of the exposures
on the current disease state using free knot regression splines
(Lindstrom, 1999; DiMatteo, Genovese, and Kass, 2001). We
have implemented a fully data-driven, adaptive knot selection
scheme that identiﬁes the optimal number and location of the
knots in both the trajectory and inﬂuence functions via re-
versible jump Markov chain Monte Carlo algorithms (Green,
1995; Botts and Daniels, 2008). Analysis is carried out in a hi-
erarchical Bayesian framework. Our modeling framework can
accommodate any possible nonlinear time-varying pattern in
the exposure and inﬂuence proﬁles, and thus oﬀers additional
ﬂexibility over a fully parametric formulation. Moreover, the
joint Bayesian model ensures proper propagation of uncer-
tainty via an integrated computational scheme. An additional
aspect of our article is to carry out model checking and assess-
ment using various functions of the risk scores that we deﬁne
in Section 5.
Remark 1: A natural question that may arise in this con-
text is the issue of prospective and retrospective equivalence
under such a framework. We show that the equivalence re-
sults of Seaman and Richardson (2004) applies to the pro-
posed semiparametric framework thus enabling us to perform
the analysis based on a prospective likelihood even though a
case–control study is retrospective in nature.
The remaining sections are organized as follows. In
Section 2, we describe the Beta Carotene Retinol Eﬃcacy
Trial and the related prostate cancer dataset which motivated
our study. In Section 3, we introduce the details of our semi-
parametric modeling approach. Section 4 describes posterior
inference and introduces the adaptive knot selection scheme.
Section 5 outlines the model comparison and assessment pro-
cedures. We describe the data analysis results based on the
prostate cancer dataset in Section 6 and end with a discussion
in Section 7. Details regarding the adaptive knot selection al-
gorithms and the Bayesian equivalence results are included in
the supplementary materials (Web Appendix).
2. Example: Prostate Cancer Study from the Beta
Carotene and Retinol Eﬃcacy Trial (CARET)
We illustrate our methodology using a dataset from
the CARET, a randomized trial conducted by the Fred
Hutchinson Cancer Research Center. The current dataset is
designed to study the association between prostate cancer
and prostate-speciﬁc antigen (PSA) and has previously been
used to assess the predictiveness of PSA as a biomarker-based
screening procedure for prostate cancer (Etzioni et al., 1999).
Participants in this study included men aged from 50 to
65 years at high risk of lung cancer. They were randomized to
receive either placebo or Beta Carotene and Retinol. From the
initial CARET cohort of 12,025 men, 354 men were diagnosed
as having prostate cancer. The intervention had no noticeable
eﬀect on the incidence of prostate cancer, with similar number
of cases observed in the intervention and control arms. Of the
354 prostate cancer cases, 75 had three to eight blood samples
taken as far back as 10 years prior to diagnosis. The individ-
uals deemed “controls” were selected among individuals not
yet diagnosed as having either prostate or lung cancer by the
time of analysis. The levels of free and total PSA were retro-
spectively assayed in the sera of 71 prostate cancer cases and
70 age-matched controls with similar duration in the study
as the cases. These 71 prostate cancer cases were diagnosed
between September 1988 and September 1995 inclusive. Be-
cause the cases and the controls were selected at the time of
analysis, after the completion of the follow-up period of the
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trial, and the blood samples retrospectively assayed, this per-
fectly ﬁts the setup of a case–control study that is embedded
within a large cohort study with longitudinal exposure history
available on cases and controls.
As the exposure variable, we use the natural logarithm of
the total PSA (Ptotal) (secondary analyses with the negative
logarithm of the ratio of free to total PSA (Pratio) reveal
similar ﬁndings). Etzioni et al. (1999) analyzed this dataset by
modeling the receiver operating characteristic (ROC) curves
associated with both the biomarkers (Ptotal and Pratio) as a
function of the time with respect to diagnosis. They observed
that although the two markers performed similarly 8 years
prior to diagnosis, Ptotal was superior to Pratio in terms of
its predictive performance at times closer to diagnosis. Thus,
throughout the article the term PSA is used to denote Ptotal
as the exposure of interest.
Remark 2: Note that though the sampling scheme appears
to be closely related to a nested case–control design (Lubin
and Gail, 1984), there is a fundamental technical diﬀerence.
In a nested case–control study, incidence density sampling is
used, where at a failure time, say, t, at which the case occurs,
a control is selected from the disease-free risk set, i.e., a set
of individuals who are disease-free at time t. Thus a control
at time t can become a case at a future time point. The usual
analysis for a nested case–control design will thus use the par-
tial/conditional likelihood framework, where the controls are
selected from the disease-free risk sets at time t at which the
case occurs (Prentice and Breslow, 1978). For time-varying
exposures (Samuelson, 1997; Essebag et al., 2005), one may
need more than one control corresponding to each case un-
der a nested case–control design for better ﬁnite sample per-
formances. However, we are simply adopting an unmatched
case–control design after the conclusion of the study and try-
ing to create a measure of cumulative exposure when longi-
tudinal exposure history is available for cases and controls.
We are not using PSA measures directly as a time-varying
covariate in the disease risk model. If cases and controls are
individually matched, say in terms of age and duration in the
study, the unconditional logistic model can be extended to a
stratiﬁed logistic regression model and similar Bayesian esti-
mation can proceed with a prior distribution corresponding
to the matched set speciﬁc nuisance parameters (Rice, 2008).
We adjusted for age in our unconditional logistic regression
model as the dataset did not include enough information to
identify the individually matched case–control pairs. Etzioni
et al. (1999) also adopted this unmatched analytic strategy
by adjusting for matching covariates, instead of a conditional
likelihood approach.
3. Model Speciﬁcation
3.1 Notation
Let Yij be the j th exposure (PSA) observation recorded for
the i th subject, aij the age of the i th subject when the j
th PSA observation is collected, and tij denotes the time (in
years) of the j th PSA measurement relative to the time of
diagnosis for the i th subject (i = 1, . . . ,N; j = 1, . . . , ni ). For
cases, time of diagnosis is the time when cancer was detected
and no PSA measurement at or after that time is used for
our modeling purposes. For controls, time of diagnosis is syn-
onymous to the last available observation time or the time of
normal digital rectal examination. Denoting the age at diag-
nosis of the i th subject by adi , we have, aij = tij + a
d
i . This
relationship will be used below to simplify notation.
3.2 Model Framework
Our framework is composed of two models - (1) A trajectory
model for the longitudinal exposure proﬁle and (2) a disease
risk model for the eﬀect of the exposure trajectory on the
binary disease outcome. Inference on these two models will
be done simultaneously, and is described in Section 4.
Our modeling framework resembles that of Zhang, Lin, and
Sowers (2007) who used a two-stage functional mixed model
approach for modeling the eﬀect of a longitudinal exposure
proﬁle on a continuous outcome. They proposed a linear func-
tional mixed eﬀects model for modeling the repeated mea-
surements on the exposure values. The eﬀect of the exposure
proﬁle on the continuous outcome was modeled via a partial
functional linear model. They treated the unobserved, true
subject-speciﬁc exposure trajectory as a functional covariate.
For ﬁtting purposes, they developed a two-stage nonparamet-
ric regression calibration method using smoothing splines. By
using the relation between smoothing splines and mixed mod-
els, estimation at both stages was conveniently cast into a
uniﬁed mixed model framework. The key diﬀerence between
their framework and ours is that we use Bayesian inferential
techniques to simultaneously estimate the parameters of the
exposure and disease risk models. The adaptive knot selection
allows for the smoothness to vary over the domain on which
the function is deﬁned. In addition, instead of a linear mod-
eling framework, we use a combination of linear and logistic
models because our exposure is continuous and the response
is binary.
3.2.1 Exposure trajectory model. For the exposure trajec-
tory model, we assume
Yij = Xi (aij ) + eij
= f (aij ) + gi (aij ) + eij
= f
(
tij + adi
)
+ gi
(
tij + adi
)
+ eij , (1)
where Xi (t + adi ) is the true (error-free) unobserved subject-
speciﬁc exposure proﬁle modeled as f (t + adi ) + gi (t + a
d
i ),
f (.) is the population mean function of the overall PSA trend
as a function of age for all the subjects, gi (.) is the subject-
speciﬁc deviation function reﬂecting the deviation of the i th
subject speciﬁc proﬁle from the mean population proﬁle, and
eij ∼ N(0, σ2e).
The reason for modeling exposure as a function of age is
that, for a randomly chosen subject with unknown disease
status, the PSA value at a certain time point should depend
on the subject’s age at that time point, not their time with
respect to diagnosis. In other words, the same exposure ob-
servation recorded at the same time relative to diagnosis for
two subjects with diﬀerent age values should not be treated
as same.
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We represent both f (aij ) and gi (aij ) using regression splines
as follows:
f (aij ) = β0 + β1aij + · · ·+ βp apij +
K∑
k=1
βp+k (aij − τk )p+
= Φp ,τ (aij )′β,
gi (aij ) = bi0 + bi1aij + · · ·+ biqaqij +
M∑
m =1
bi,q+m (aij − κm )q+
= Φq ,κ (aij )′bi , (2)
where Φp ,τ (aij ) = [1, aij , . . . , a
p
ij , (aij−τ1)p+, . . . , (aij − τK )p+]′
and Φq ,κ (aij ) = [1, aij , . . . , a
q
ij , (aij − κ1)q+, . . . , (aij − κM )q+]′
are truncated polynomial basis functions of degrees p and
q with knots (τ 1, . . . , τK ) and (κ1, . . . , κM ), respectively.
Typically, M ≤ K.
3.2.2 Disease risk model. The prospective disease risk
model is assumed to be of the form
P
(
Di = 1|Xi
(
t + adi
)
,−c1 ≤ t ≤ −c2
)
= L
(
α + δadi +
∫ −c 2
−c 1
Xi
(
t + adi
)
γ(t)dt
)
, (3)
where L(.) is the logistic link function (L(u) = {1 + exp
( − u)}−1) and γ(t) is an unknown smooth function of time
(with respect to diagnosis). We have treated age at diagno-
sis as a separate covariate in the disease model to account
for the confounding eﬀect of age on the association between
PSA proﬁle and the probability of disease. Lastly, c1 and c2
demarcate the length of the exposure history for the i th sub-
ject; e.g., c1 = 8 and c2 = 2 would imply that, for the i th
subject, exposure observations recorded between 8 years to
2 years prior to diagnosis are being considered for analysis.
Remark 3: The function of interest in disease model (3) is
γ(t): the inﬂuence function. This function provides the ability
to capture a temporally varying relationship of a longitudi-
nal trajectory on the current disease status of a subject. This
is particularly important for studies dealing with the associ-
ation of a longitudinal covariate/exposure and a continuous
or discrete outcome. In our application, γ(t) captures the un-
derlying association pattern between the PSA exposure tra-
jectory and the probability of prostate cancer as a function
of the time with respect to diagnosis. Another point to note
is that by varying c1 and c2, we can select diﬀerent lengths
of PSA trajectories (across subjects) and can examine their
eﬀect on the current disease status. Similarly, as discussed in
Section 6.3, using the disease risk model in (3), we can create
odds ratios comparing the eﬀects of certain typical exposure
trajectories, like a ﬂat versus an exponential trajectory.
In the most general case, γ(t) can also be represented by a
regression spline, i.e.,
γ(t) = Ψr,ξ (t)′φ, (4)
where Ψr,ξ (t) = [1, t, . . . , tr , (t− ξ1)r+, . . . , (t− ξK∗)r+]′,φ =
(φ0, . . . , φK∗+r )′ and (ξ1, . . . , ξK∗) are the knots.
Replacing (2) and (4) in the right-hand side of (3), we have
P
(
Di = 1
∣∣Xi(t + adi ),−c1 ≤ t ≤ −c2)
= L
(
Ad
′
i θ + β
′Miφ + b′iQiφ
)
, (5)
where Adi =(1, a
d
i ), θ=(α, δ), Mi=
∫ −c 2
−c 1 Φp ,τ (t+a
d
i )Ψr,ξ (t)
′dt
and Qi =
∫ −c 2
−c 1 Φq ,κ (t + a
d
i )Ψr,ξ (t)
′dt.
For pre-chosen degrees of the basis functions and a given
set of knot locations and numbers, both Mi and Qi are ma-
trices and are available in closed form. As will be explained
in Section 4.3, adaptive knot selection techniques will be used
to identify the optimal number and location of knots for Xi (.)
and γ(.), respectively.
Remark 4: Because we had a relatively small dataset, we
have used the following simpliﬁed version of the trajectory
model to analyze the prostate cancer dataset.
Yij = β0 + β1
(
tij + adi
)
+
K∑
k=1
βk+1
(
tij + adi − τk
)
+
+ bi
(
tij + adi
)
+ eij
= Φ
(
tij + adi
)′
β + bi
(
tij + adi
)
+ eij , (6)
where eij ∼ N(0, σ2e), bi ∼ N(0, σ2b). Consequently, the disease
model simpliﬁes to
P
(
Di = 1
∣∣Xi(t + adi ),−c1 ≤ t ≤ −c2)
= L
(
α + δadi +
∫ −c 2
−c 1
Xi
(
t + adi
)
γ(t)dt
)
= L
(
Ad
′
i θ + β
′Miφ + biQiφ
)
. (7)
The posterior calculations will be based on the above pa-
rameterization.
4. Posterior Inference
4.1 Likelihood Function
Let Yi = (Yi1, . . . , Yin i )
′ and Di denote the exposure vec-
tor and disease status and ai = (ai1, . . . , ain i )
′ and ti =
(ti1, . . . , tin i )
′ be the observed values of age and time with
respect to diagnosis for the i th subject, respectively. So, the
response vector for the i th subject is the pair (Yi , Di ). Let
Ω = (β, σ2e , b, σ2b , θ,φ) be the set of unknown parameters cor-
responding to the exposure and disease models in (6) and (7).
Because the optimal number and location of knots will be
chosen in a data-driven manner, they will also be regarded
as unknown parameters and will be simultaneously estimated
through a fully Bayesian mechanism. Let k1 and k2 be the
number of knots for the exposure and disease risk models,
respectively, where 0 ≤ k1 ≤ K1 and 0 ≤ k2 ≤ K2, K1 and
K2 being ﬁxed. Let (τ1, . . . , τk 1 ) and (ξ1, . . . , ξk 2 ) denote the
corresponding knot locations such that
aE < τ1 < · · · < τk 1 < bE , and aD < ξ1 < · · · < ξk 2 < bD .
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The likelihood function is given by
L(Ω, k1, k2, τ , ξ|y,D) =
N∏
i=1
n i∏
j=1
p(Yij |β, bi , σ2e , k1, τ )
×
N∏
i=1
p(bi |σ2b )
N∏
i=1
p(Di |θ,β,φ, k2, ξ),
(8)
where p(Yij |.) denotes the normal probability distribution cor-
responding to the trajectory model, p(bi |σ2b) is the normal dis-
tribution for the random subject speciﬁc slope coeﬃcients and
p(Di |.) is the Bernoulli distribution with success probability
given by the logistic link function for the disease risk model
in (7).
4.2 Priors
To complete the speciﬁcation of our model, we assign
prior distributions on the unknown parameters. We as-
sume normal and inverse gamma priors for the parame-
ters, i.e., β ∼ N (0, σ2β I), θ ∼ N (0, σ2θ I),φ ∼ N (0, σ2φ I), σ2e ∼
IG(a0, b0), σ2b ∼ IG(a1, b1), σ2β ∼ IG(a2, b2), and σ2φ ∼ IG(a3,
b3), where IG stands for inverse gamma density and (ai , bi )
(i = 0, 1, 2, 3) are ﬁxed hyperparameters. We use σ2θ = 100,
a0 = 0.1, b0 = 0.1, a1 = 0.1, b1 = 0.1, a2 = 3, b2 = 3, a3 = 3, and
b3 = 3. We also considered other values for (a2, b2) and (a3, b3)
such as (0.1, 0.1), (1, 1), (2, 2), and (4, 4). However, inferences
were not very sensitive to the choice of hyperparameters.
For the knot numbers k1 and k2, we put Poisson priors with
means μ1 and μ2 such that μ1 = μ2 = 1. Because there is no
reason a priori to favor knots at any particular locations on
the domain of Xi (.) and γ(.), we put ﬂat priors on both τ and
ξ, i.e.,
π(k1) = Poisson(μ1)I(0 ≤ k1 ≤ K1),
(τ |k1) ∼ Uniform(aE, bE )I
(
aE < τ1 < · · · < τk 1 < bE
)
⇒ π(τ |k1) = k1!(bE − aE )k 1 I
(
aE < τ1 < · · · < τk 1 < bE
)
.
π(k2) = Poisson(μ2)I(0 ≤ k2 ≤ K2),
(ξ|k2) ∼ Uniform(aD, bD )I
(
aD < ξ1 < · · · < ξk 2 < bD
)
⇒ π(ξ|k2) = k2!(bD − aD )k 2 I(a
D < ξ1 < · · · < ξk 2 < bD ).
Because the knot locations and numbers are assumed to
be independent, the joint prior distribution is given by
π(k1, k2, τ , ξ) = π(k1)π(τ |k1)π(k2)π(ξ|k2).
4.3 Posterior Inference
Because the trajectory model in (1) has a linear form and the
disease risk model (3) has a logistic structure, the resulting
likelihood and posterior do not have a tractable closed form.
To facilitate computations, we approximate the logistic dis-
tribution as a mixture of normals, using a well-known data
augmentation algorithm proposed by Albert and Chib (1993)
for posterior sampling. For details, see the supplementary web
appendix.
The joint posterior distribution of the parameters and the
knots location/numbers is given by
p
(
Ω, σ2β , σ
2
φ , k1, k2, τ , ξ|y,D
)
∝ L(Ω, k1, k2, τ , ξ|y,D)p
(
β|0, σ2β I
)
p
(
θ|0, σ2θ I
)
p
(
φ|0, σ2φ I
)
× IG
(
σ2e |a0, b0
)
IG
(
σ2b |a1, b1
)
IG
(
σ2β |a2, b2
)
× IG
(
σ2φ |a3, b3
)
π(k1, k2, τ , ξ),
where L(Ω, k1, k2, τ , ξ|y,D) is given in (8) and the other
terms are the prior distributions on the parameters. Our main
parameter of interest is φ, the eﬀect of integrated exposure
history on disease risk, as shown in (4). Because, the marginal
posterior distribution of φ is analytically intractable, we have
used a reversible jump Markov chain Monte Carlo algorithm
(Green, 1995) to simultaneously sample the parameters, knot
locations, and positions in an integrated manner from their
respective full conditionals (the details are given in the sup-
plementary materials).
5. Model Comparison and Assessment
To compare models and determine their discriminative abil-
ity, we calculated the risk scores from the ﬁtted “regression
part” for the cases and controls ignoring the intercept. The
reason for ignoring the intercept is that it is not meaningful
given that we are using a prospective likelihood for a retro-
spective study. At iteration m of the Markov chain Monte
Carlo sampler, the risk score for the i th individual is given
by
R
(m )
i = δ
(m )adi +
∫ −c 2
−c 1
X
(m )
i
(
t + adi
)
γ(m )(t)dt,
where δ(m) is the sampled observation of δ at iteration m and
X(m)i (.) and γ
(m)(.) are the same for the exposure trajectory
and the inﬂuence function. So, at the m th iteration, we have
a vector of posterior estimates of risk scores for all the sub-
jects, R(m ) = (R(m )1 , R
(m )
2 , . . . , R
(m )
N ). We calculate the Spear-
man rank correlation coeﬃcient between R(m ) and the vector
of original disease status vectors D = (D1, D2, . . . , DN ) given
by
ρ(m ) =
N∑
i=1
(
R
(m )∗
i − R¯(m )
∗)
(D∗i − D¯∗)[
N∑
i=1
(
R
(m )∗
i − R¯(m )
∗)2 N∑
i=1
(D∗i − D¯∗)2
]1/2 , (9)
where R(m )
∗
i are the ranks and R¯
(m )∗ is the mean of the ranks
for the risk scores, R(m)i ; D
∗
i ; and D¯
∗ are deﬁned similarly for
the disease indicators, Di . Posterior summaries of ρ(m) can be
taken as a measure of the model’s discriminative ability be-
cause these do not involve the intercept in the disease model
unlike related approaches (e.g., posterior predictive loss and
area under the curve). Clearly, we want ρ to be close to one
(and far from zero). As a tool for comparison, we compute
posterior summaries of ρ for simpler and complex models
and also for varying trajectory lengths as will be shown in
Section 6.
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For the m th iteration, we also compute the quantities
S
(m )
1 =
∑
i :D i =1
R
(m )
i /N1 and S
(m )
0 =
∑
i :D i =0
R
(m )
i /N0,
(10)
which are the averages of the posterior estimates of risk scores
for the cases and controls (N0 and N1 being the number of con-
trols and cases, respectively). We can examine the posterior
distribution of S (m)1 and S
(m)
0 and their diﬀerence. These quan-
tities would give us a measure of the degree of separation be-
tween the cases and controls provided by our model and thus
would inform on how well we can distinguish between the two
groups.
6. Analysis of Prostate Cancer and PSA History
We use the semiparametric framework explained in Section 3
to analyze the prostate cancer dataset described in Section 2.
Multiple observations on free and total PSA were obtained for
71 prostate cancer cases and 70 controls. For some subjects,
observations were collected as far back as 10 years prior to di-
agnosis. We use the natural logarithm of total PSA (Ptotal)
as our exposure of interest. Our principal aim is to exam-
ine whether past exposure observations can contribute sig-
niﬁcantly toward predicting the current disease status of a
subject given his/her current exposure information. In doing
so, we will also test how diﬀerential lengths of the PSA trajec-
tories aﬀect the current probability of disease for a particular
individual.
As mentioned in Remark 4 in Section 3, we have used a
simpliﬁed version of the trajectory and disease risk models
given in (6) and (7) to analyze our dataset. In doing so, we
examined the eﬀect of varying lengths of exposure trajectories
on the current disease state by choosing diﬀerent values of c1
and c2 in the disease model.
We did a small sensitivity analysis by changing the hyper-
parameters of the inverse gamma priors on σ2β and σ
2
φ . The
results were not very sensitive to the choice of these parame-
ters (results not shown).
6.1 Overall Model Comparison
We calculated the posterior means and 95% conﬁdence in-
tervals of the risk measures mentioned in (9) and (10) for
the diﬀerent exposure intervals. These are denoted by (a)
ρ: Spearman’s rank correlation coeﬃcient between the risk
scores and disease status for all the subjects; (b) R1: Mean
of the risk scores for cases; (c) R0: Mean of the risk scores
for controls and (d) Rd = R0 − R1: diﬀerence between the
mean risk scores for the controls and cases. The results are
shown in Table 1. Based on these measures, we conclude that
the disease risk model ﬁtted to the exposure interval I =
[ − 10, 0] had the best performance. In particular, the model
with this interval had the highest negative values of the diﬀer-
ence Rd (−2.33) (the greatest separation of the risk scores be-
tween the cases and controls) and the largest value for Spear-
man’s correlation, ρ(0.68); in an absolute sense, a correlation
of 0.68 is quite large. In the next section, we ﬁt some sim-
pler models to illustrate the increased information that can
be gained from our approach.
6.1.1 Comparison with simpler models. The disease risk
model as given in (7) is quite general in that it takes into
account age (at diagnosis) and the PSA trajectory of a
Table 1
Values of the risk score measures corresponding to diﬀerent
intervals. The 95% credible intervals are also given for the
optimal model based on I = (−10, 0 ) and the simpler
alternative models Mj : j = 0, 1, 2
Risk score measures
Intervals Rd ρ
(−3, 0) −2.06 0.66
(−5, 0) −2.12 0.67
(−8, 0) −2.27 0.67
(−10, 0) −2.33 (−3.26, −1.55) 0.68 (0.64, 0.71)
(−10, −5) −1.98 0.65
(−12, 0) −2.23 0.67
M 0 −0.28 (−0.74, 0.18) 0.08 (−0.11, 0.11)
M 1 −2.04 (−2.76, −1.42) 0.66 (0.65, 0.67)
M 2 −1.95 (−2.73,−1.30) 0.65 (0.62, 0.69)
subject into account and also incorporates the inﬂuence pat-
tern of the trajectory on the disease probability. Clearly, sim-
pler versions of this framework are possible. As such, we ﬁt
the following three models:
(1)M 0 : P
(
Di = 1|adi
)
= L
(
α + δadi
)
,
(2)M 1 : P
(
Di = 1|adi
)
= L
(
α + δadi + ϕY

ij
)
,
(3)M 2 : P
(
Di = 1|adi , Xi (t + adi )
)
= L
(
α + δadi + γ
∫ −c2
−c1 Xi (t + a
d
i )dt
)
,
where Y ij is the last observed PSA value for subject i. The
models correspond to, respectively, ignoring any PSA infor-
mation and only using age at diagnosis, using the last ob-
served PSA value and age at diagnosis, and using the area
under the PSA curve as a covariate with age at diagnosis.
For each of these three models, Table 1 shows the posterior
estimates of the risk measures. Model M0 that just included
age at diagnosis was unable to separate the cases and controls
at all. Models M1 and M2 did well but provided less separa-
tion of the risk scores and a lower correlation. In addition,
model M1 provided a similar correlation and separation to
the general model with the interval (−3, 0), which is not sur-
prising as this interval typically contained the last observed
PSA value. Overall, these results support the notion that the
semiparametric modeling implemented here for incorporating
the exposure (or PSA) trajectory/history was worthwhile for
these data, though the strength of evidence for the complex
model was limited to some extent by the small sample size
and the “noisy” observed PSA trajectories.
6.2 Shapes of the Trajectory and Inﬂuence Functions
Figures 1a and b show the plots of the population mean ex-
posure trajectory and the inﬂuence function and the corre-
sponding 95% conﬁdence bands as obtained from the pos-
terior samples of the parameters and knots. The former is
plotted against age whereas the latter is plotted against the
time with respect to diagnosis. The posterior distribution of
the number of knots for both functions placed most of their
mass at one knot (0.93 for the exposure model and 0.70 for
the disease model) with the nonlinearity evident a little after
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Figure 1. Plot of the exposure trajectory against age and the inﬂuence proﬁle against the time with respect to diagnosis for
the PSA data.
age 75 for the exposure trajectory and a slight nonlinearity
in the inﬂuence function (though it is close to linear). The
posterior mean of the exposure trajectory conﬁrms the fact
that the PSA observations tend to increase steadily with age.
The pattern is more or less linear for the entire age range.
However, there is a sharp upward turn near about age 77 (as
mentioned above) when the PSA values increase further. On
the other hand, the inﬂuence of the PSA proﬁle on the current
disease status has an increasing pattern as we move closer to
the point of diagnosis. This is intuitive because the eﬀects of
exposure observations collected closer to the point of diagno-
sis would be expected to have a higher inﬂuence (weight) on
the current disease status than those collected further back
in time. In addition, the sign of γ(t) (see Figure 1b with posi-
tive values for the ﬁrst 5 years before diagnosis, and negative
values for second 5 years) indicates that the function, γ(t)
captures the diﬀerential direction of the eﬀect of PSA values
closer to diagnosis versus those farther back in time.
6.3 Inference on Odds Ratios
To better understand the relationship between PSA trajec-
tory and the probability of prostate cancer, we compute sev-
eral odds ratios. In particular, we compute the posterior dis-
tribution of the log odds of prostate cancer corresponding to
some reasonable shapes of exposure trajectories (in what fol-
lows, comparing a trajectory Xi to a trajectory Zi ) based on
our data.
In the following, we denote the diﬀerent comparisons by
C1, C2, C3 and, C4. For each of these comparisons, we de-
note by l and u, the lower and upper limits of the trajectories.
For C1–C3, the level of the baseline (ﬂat) trajectory Xi is
the average of the lower and upper limits of the increasing
trajectory, Zi , i.e., (l + u)/2. Based on our data, we choose
l = 0.1 and u = 0.9 (these are the lowest and highest values of
PSA for one of the subjects in the dataset) and l = .039 and
u = 1.37 (these are the 25th and 75th percentiles of the
observed PSA values, respectively).
C1:Xi
(
t + adi
)
= (l + u)/2, Zi
(
t + adi
)
= νζt+a
d
i ,
−c1 ≤ t ≤ −c2.
Here we compare the log odds of disease corresponding to a
ﬂat trajectory to an exponentially increasing one. The values
of ν and ζ that yield l and u are given by
ν = l
(
l
u
)(c 1−a di )/ (c 2−c 1)
and ζ =
(
l
u
) 1
c 2−c 1
.
The log-odds ratio for this comparison is given by
LOR1 =
∫ −c 2
−c 1
(
νζt+a
d
i − (l + u)/2
)
γ(t)dt.
C2:Xi (t + adi ) = (l + u)/2, Zi (t + a
d
i ) = ν + ζ(t + adi ),
−c1 ≤ t ≤ −c2.
Here we compare the log odds of disease corresponding to a
ﬂat trajectory to a linearly increasing one. The values of ν
and ζ that yield l and u are given by
ν = l − (l − u)
(
adi − c1
)
c2 − c1 and ζ =
l − u
c2 − c1 .
The log-odds ratio for this comparison is given by
LOR2 =
∫ −c 2
−c 1
(ν + ζt+a
d
i − (l + u)/2)γ(t)dt.
C3:Xi (t + adi ) = (l + u)/2, Zi (t + a
d
i ) = ν + ζ log (t + adi ),
−c1 ≤ t ≤ −c2.
Here we compare the log odds of disease corresponding to a
ﬂat trajectory to one which is linear in the logarithmic scale.
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Table 2
Posterior means and corresponding 95% credible intervals of the log-odds ratios for comparing diﬀerent shapes of the exposure
trajectories. Here C1: horizontal–exponential, C2: horizontal–linear, C3: horizontal–logarithmic; and C4: linear-exponential
exposure proﬁles under two diﬀerent speciﬁcations of the odds ratios (a,b)
Comparisons
(a,b) C1 C2 C3 C4
(0.1,0.9) 4.51 (−0.25, 11.04) 4.80 (−0.08, 11.64) 4.79 (−0.06, 11.61) 0.29 (−0.22, 0.74)
(0.039,1.37) 6.83 (−0.55, 16.84) 8.00 (−0.13, 19.42) 8.00 (−0.11, 19.36) 1.20 (−0.12, 2.80)
The values of ν and ζ that yield l and u are given by
ν =
u log
(
adi − c1
)
− l log
(
adi − c2
)
log
(
adi − c1
)
− log
(
adi − c2
) and
ζ =
l − u
log
(
adi − c1
)
− log
(
adi − c2
)
The log-odds ratio for this comparison is given by
LOR3 =
∫ −c 2
−c 1
(
ν + ζ log
(
t + adi
)
− (l + u)/2
)
γ(t)dt.
C4:Xi (t + adi ) = ν0ζ
t+adi0 , Zi (t + adi ) = ν1 + ζ1(t + a
d
i ),
−c2 ≤ t ≤ −c1.
Here we compare the log odds of disease corresponding to
a exponentially increasing trajectory to a linearly increasing
one. The values of ν and ζ that yield l and u are given by
ν0 = l
(
l
u
)(c 1−a di )/ (c 2−c 1)
, ζ0 =
(
l
u
) 1
c 2−c 1
ν1 = l −
(l − u)
(
adi − c1
)
c2 − c1 , ζ1 =
l − u
c2 − c1 .
The log-odds ratio for this comparison is given by
LOR4 =
∫ −c 2
−c 1
(
ν1 + ζ1
(
t + adi
)
− ν0ζt+a
d
i
0
)
γ(t)dt.
Table 2 reports the posterior means and 95% credible in-
tervals of the log-odds ratios for the above four comparisons
and the two choices of upper and lower limits. The log-odds
ratios for the ﬁrst three comparisons (horizontal–exponential,
horizontal–linear, and horizontal–logarithmic) are marginally
signiﬁcant (with credible intervals barely covering zero) and
fairly similar. The similarity between these three is not sur-
prising because the form of the inﬂuence function γ(t) cap-
tures a contrast between early and late PSA values and the
comparison of each is with respect to a stable (ﬂat) PSA tra-
jectory at the midpoint of the increasing ones (in fact, if the
level of the ﬂat trajectory is set at the lower limit of the in-
creasing ones, i.e., at l, all the log odds are more extreme and
signiﬁcant). The log-odds ratios for both choices of the lower
and upper limits, (l, u) are quite large and indicate a much
higher odds of prostate cancer for an increasing PSA trajec-
tory versus one that is stable. These odds ratio measures are
not comparable with a simple logistic regression model that
is linear in the last available PSA observation (estimated log
OR of 1.2) because here we are using the entire longitudinal
trajectory and an inﬂuence function that greatly aﬀects the
magnitude and interpretation of the point estimates obtained.
The odds ratio for the fourth comparison, a linear trajectory
versus an exponentially increasing one (that both start and
end at the same values), is also marginally signiﬁcant for both
cases and shows the power of this modeling approach with the
ability to utilize the actual shape of the trajectories to better
estimate the odds of prostate cancer.
Overall, our results indicate that for future retrospective
assays of stored serum samples for individuals at risk for
prostate cancer, it would be informative to go back up to
10 years prior to diagnosis.
7. Discussion
Using longitudinal exposure trajectories in a case–control de-
sign is a relatively unexplored area. Recent developments
in the area of semiparametric and nonparametric regression
analysis have provided techniques to capture exposure trajec-
tories that have complicated and unknown functional forms.
We have used free knot regression splines in modeling the ex-
posure trajectories for the cases and the controls. However,
the trajectory model in our application lacks a random (sub-
ject speciﬁc) intercept due to the small sample size and lack
of heterogeneity. Our framework can be used even when expo-
sure observations are collected at diﬀerent time points across
subjects, i.e., when the study design is unbalanced in nature.
The exposure trajectory is used as the predictor in a prospec-
tive logistic model for the binary disease outcome. We have
additionally modeled the slope parameter of the disease risk
model as a regression spline to account for any time-varying
inﬂuence pattern of the exposure trajectory on the current
disease status. We have integrated an adaptive knot selec-
tion mechanism by which the optimal position and locations
of the knots for both the exposure trajectory and inﬂuence
functions are simultaneously selected in a data-driven man-
ner. Overall, the proposed method appropriately accounts for
the generated uncertainty of this multilevel approach.
To simplify the analysis, we used the logit-mixture of nor-
mal approximation (Albert and Chib, 1993). We also estab-
lished that the Bayesian equivalence results of Seaman and
Richardson (2004) holds for our framework, thus allowing us
to use a prospective logistic model having fewer nuisance pa-
rameters although the dataset was collected retrospectively.
We analyzed our data using diﬀerent lengths of exposure
trajectories. In doing so, we have concluded that past ex-
posure observations do provide signiﬁcant information to-
ward predicting the current disease status of a subject. We
Incorporating Exposure History in Case–Control Studies 369
performed model comparison and assessment by calculating
risk scores corresponding to the cases and controls and com-
puting correlations, which are not inﬂuenced by using the
prospective likelihood (as opposed to the retrospective one).
These criteria indicated that models with longer exposure tra-
jectories tend to perform better than those with shorter tra-
jectories and that the relationship between the PSA trajectory
and disease is complex. In fact, we concluded that the model
incorporating exposure observations recorded 10 years prior
to diagnosis results in the best ﬁt to the dataset. Based on
the model comparison tools we used, it seemed that PSA ob-
servations collected prior to 10 years before diagnosis provide
minimal additional information in explaining the current dis-
ease status above and beyond those collected up to 10 years
prior to diagnosis (although the available exposure data be-
yond 10 years was quite sparse). We have also conﬁrmed that
conditional on age at diagnosis, the exposure trajectory con-
tains signiﬁcant amount of information on the current disease
status of a subject and thus should be included in the dis-
ease risk model. We showed that by doing so, the model per-
formance improves signiﬁcantly compared to last observation
carried forward analysis.
Some interesting extensions remain under consideration
for future research. For richer datasets, it will be interest-
ing to implement the completely ﬂexible formulation with
the subject-speciﬁc deviation functions also represented as
regression splines. Extending the analytic approaches to the
set-up of a serial case–control study as in Park and Kim
(2004), which has the additional complexity of correlated
time-varying response variable, is also an open problem.
8. Supplementary Materials
Web Appendices, Tables, and Figures referenced in Sections 1,
4.3, and 6.1–6.3 are available under the Paper Informa-
tion link at the Biometrics website http://www.biometrics.
tibs.org.
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